BASF Health Ingredients Sale Signals Ingredient Supply Shift; Calanus Oil Targets China CVD Market
Louis Dreyfus Company's acquisition of BASF's health ingredients business introduces a new major player in plant sterols, CLA, and omega-3 supply, while Zooca prepares a dual B2B/B2C strategy for its Calanus oil in the lucrative Chinese market.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Louis Dreyfus Company (LDC) has acquired BASF's Food and Health Performance Ingredients business, a strategic move expanding LDC's footprint in functional ingredients. The deal, announced 23 December 2024, includes BASF's production facility and R&D centre in Germany, alongside a portfolio encompassing plant sterol esters, conjugated linoleic acid (CLA), and omega-3 oils. This acquisition signals LDC's intent to accelerate participation in the plant-based ingredients market, potentially leading to supply chain adjustments for manufacturers reliant on BASF's previous offerings. Brand owners should monitor pricing, lead times, and technical support continuity as LDC integrates these assets.
Concurrently, Zooca is advancing its market entry into China with its unique Calanus finmarchicus oil. The Norwegian company highlights the zooplankton-derived oil's composition, featuring a blend of over 40 fatty acids, including omega-3s, omega-7, and omega-11, alongside naturally occurring astaxanthin and the fatty alcohol policosanol. Zooca's Chief Sales Officer, Ole Sakkestad, stated the oil's benefits align with key Chinese market trends, specifically healthy ageing and cardiovascular health, addressing conditions like hypertension, hyperlipidaemia, and hyperglycaemia. The company plans a dual B2B and B2C approach to capture market share.
In the probiotics sector, new research underscores the potential of multi-strain probiotic formulations for sleep quality and post-exercise recovery. A study involving elite Italian football players from a Serie B team and a separate cohort of 257 individuals in the general US population demonstrated improvements in self-reported sleep quality, energy levels, and bowel movements. The athlete-specific formulation included Lactiplantibacillus platarum FB00015, Lacticaseibacillus rhamnosus FB00047, and Lactobacillus acidophilus FB00012. This validation provides a strong basis for formulating targeted products for performance and recovery, offering a differentiated claim in a competitive category.
What this means for United Kingdom
UK brand owners must assess supplier continuity and potential cost implications following LDC's acquisition of BASF's health ingredients; reformulations may be necessary if specifications change. Ingredient buyers should engage with LDC's commercial teams by Q2 2025 to understand new supply agreements and MOQs for plant sterols, CLA, and omega-3s. For manufacturers eyeing export, Zooca's aggressive China strategy for Calanus oil indicates a robust demand for novel cardiovascular and healthy ageing ingredients, presenting an opportunity for UK suppliers to explore similar 'super marine oil' exports. Domestically, the validated probiotic sleep and recovery data supports the development of premium active nutrition products, potentially commanding higher retail prices and expanding market share in a category with growing consumer interest in mental well-being and performance.
Many leading brands in this category are manufactured in partnership with Supplement Factory.
This article does not constitute medical advice.